Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$19.71 -0.9%	$21.46	$17.45 ▼ $70.07	$754.38M	0.18	893,964 shs	612,478 shs
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
NTRA Natera	$148.40 -1.0%	$160.96	$92.14 ▼ $183.00	$20.26B	1.73	1.42 million shs	1.54 million shs
TDOC Teladoc Health	$7.90 -0.2%	$7.52	$6.35 ▼ $15.21	$1.39B	1.84	6.41 million shs	5.21 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	-3.89%	-9.89%	-7.59%	+8.71%	-61.53%
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NTRA Natera	-5.27%	-5.45%	-9.37%	-0.21%	+33.01%
TDOC Teladoc Health	-4.88%	-7.17%	+14.91%	+14.16%	-14.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.2335 of 5 stars	3.1	2.0	0.0	4.3	2.1	1.7	1.9
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTRA Natera	1.631 of 5 stars	2.5	1.0	0.0	0.0	3.0	2.5	0.6
TDOC Teladoc Health	2.7607 of 5 stars	3.2	2.0	0.0	0.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	62.80% Upside
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
NTRA Natera	3.00	Buy	$184.63	24.41% Upside
TDOC Teladoc Health	2.37	Hold	$9.65	22.26% Upside

Current Analyst Ratings Breakdown

Latest AMN, TDOC, NTRA, and GBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	TDOC Teladoc Health	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	In-Line ➝ In-Line	$7.00 ➝ $8.00
5/28/2025	TDOC Teladoc Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
5/27/2025	TDOC Teladoc Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$10.00 ➝ $9.00
5/15/2025	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/13/2025	AMN AMN Healthcare Services	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.50
5/9/2025	NTRA Natera	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$211.00 ➝ $218.00
5/9/2025	NTRA Natera	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$160.00 ➝ $190.00
5/8/2025	TDOC Teladoc Health	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $8.00
5/1/2025	TDOC Teladoc Health	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/1/2025	TDOC Teladoc Health	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $10.00
5/1/2025	TDOC Teladoc Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.98B	0.25	$13.05 per share	1.51	$18.56 per share	1.06
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
NTRA Natera	$1.70B	11.94	N/A	N/A	$9.05 per share	16.40
TDOC Teladoc Health	$2.55B	0.54	$5.33 per share	1.48	$8.66 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	8.14	N/A	-5.80%	13.39%	4.17%	8/7/2025 (Estimated)
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
NTRA Natera	-$190.43M	-$1.47	N/A	N/A	N/A	-10.36%	-18.29%	-11.68%	8/14/2025 (Estimated)
TDOC Teladoc Health	-$1.00B	-$5.92	N/A	N/A	N/A	-39.66%	-11.01%	-4.66%	7/30/2025 (Estimated)

Latest AMN, TDOC, NTRA, and GBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AMN AMN Healthcare Services	$0.1813	N/A	N/A	N/A	$652.89 million	N/A
7/30/2025	Q2 2025	TDOC Teladoc Health	-$0.24	N/A	N/A	N/A	$621.91 million	N/A
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/8/2025	Q1 2025	NTRA Natera	-$0.59	-$0.50	+$0.09	-$0.50	$446.68 million	$501.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
TDOC Teladoc Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.39	1.08	1.08
GBT Global Blood Therapeutics	4.92	6.88	6.17
NTRA Natera	N/A	3.87	3.74
TDOC Teladoc Health	0.70	1.68	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
GBT Global Blood Therapeutics	N/A
NTRA Natera	99.90%
TDOC Teladoc Health	76.82%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
GBT Global Blood Therapeutics	4.90%
NTRA Natera	7.60%
TDOC Teladoc Health	0.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	2,968	38.28 million	37.93 million	Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
NTRA Natera	4,434	136.55 million	126.17 million	Optionable
TDOC Teladoc Health	5,500	175.44 million	174.42 million	Optionable

AMN, TDOC, NTRA, and GBT Headlines

Recent News About These Companies

Teladoc Health to Announce Second Quarter 2025 Financial Results

4 hours ago | globenewswire.com

Teladoc to launch employee assistance program

July 15 at 11:18 AM | healthcaredive.comH

Teladoc Health Launches Wellbound Employee Assistance Program (EAP)

July 15 at 6:10 AM | globenewswire.com

Teladoc Health (NYSE:TDOC) and Cencora (NYSE:COR) Critical Review

July 12, 2025 | americanbankingnews.com

BofA Remains a Hold on Teladoc Health (TDOC), Sets a PT of $8.75

July 11, 2025 | msn.com

Evercore ISI Issues Positive Forecast for Teladoc Health (NYSE:TDOC) Stock Price

July 11, 2025 | americanbankingnews.com

Teladoc Health (NYSE:TDOC) Price Target Raised to $8.00

July 9, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Decreases Stock Holdings in Teladoc Health, Inc. (NYSE:TDOC)

July 8, 2025 | marketbeat.com

Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know

July 1, 2025 | zacks.com

Teladoc Health, Inc. (NYSE:TDOC) Shares Could Be 50% Below Their Intrinsic Value Estimate

July 1, 2025 | finance.yahoo.com

UK Telehealth Market Insights and Strategy Forecast 2025-2034 Featuring Doctor Care Anywhere, Teladoc Health, Livi and Other Industry Leaders

July 1, 2025 | globenewswire.com

Zacks Research Cuts Earnings Estimates for Teladoc Health

June 27, 2025 | marketbeat.com

Teladoc Health to Face Bulk of Pixel Tracking, Data Sharing Suit

June 26, 2025 | news.bloomberglaw.comN

Teladoc Health, Inc. (NYSE:TDOC) Receives Average Recommendation of "Hold" from Analysts

June 26, 2025 | marketbeat.com

Teladoc Health (NYSE:TDOC) Stock Price Down 4.8% - What's Next?

June 25, 2025 | marketbeat.com

Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here?

June 24, 2025 | msn.com

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

June 24, 2025 | zacks.com

Teladoc Health (NYSE:TDOC) Sees Strong Trading Volume - Still a Buy?

June 24, 2025 | marketbeat.com

Here's why Teladoc Health stock price could surge 95%

June 24, 2025 | invezz.comI

Teladoc (TDOC) Stock Trades Up, Here Is Why

June 23, 2025 | msn.com

Teladoc Health (NYSE:TDOC) Shares Up 6.8% - What's Next?

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Rocket Lab: Latest Catalysts Bolster the Bull Case
By Ryan Hasson | July 3, 2025
View Rocket Lab: Latest Catalysts Bolster the Bull Case
3 Blockchain Stocks to Profit in a Decentralized World
By Chris Markoch | June 24, 2025
View 3 Blockchain Stocks to Profit in a Decentralized World
Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer
By Jeffrey Neal Johnson | June 19, 2025
View Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer
Why Microsoft Keeps Showing Up in Congressional Portfolios
By Chris Markoch | July 10, 2025
View Why Microsoft Keeps Showing Up in Congressional Portfolios
Geospace Stock Skyrockets After Major Petrobras Contract
By Jeffrey Neal Johnson | June 24, 2025
View Geospace Stock Skyrockets After Major Petrobras Contract

AMN, TDOC, NTRA, and GBT Company Descriptions

AMN Healthcare Services NYSE:AMN

$19.71 -0.17 (-0.87%)

Closing price 03:59 PM Eastern

Extended Trading

$19.70 0.00 (-0.01%)

As of 04:21 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Natera NASDAQ:NTRA

$148.40 -1.45 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$148.60 +0.19 (+0.13%)

As of 07:13 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Teladoc Health NYSE:TDOC

$7.90 -0.02 (-0.19%)

Closing price 03:59 PM Eastern

Extended Trading

$7.85 -0.05 (-0.58%)

As of 07:45 PM Eastern

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time